ON COMPAREABLE OPERATIONAL BASIS*

+5.6% $6.8 BN

Strong Performance in CORE BUSINESS SEGMENTS

SALES WORLDWIDE

DIAGNOSTICS $1.3 BN

MEDICAL DEVICES $2.6 BN

NUTRITION $1.8 BN

ESTABLISHED PHARMACEUTICALS $1.2 BN

Breakthrough Invention in MEDICAL DEVICES

FREESTYLE® LIBRE

Now approved in the U.S.

This revolutionary system replaces blind glucose monitoring, eliminating the need for routine finger sticks.**

HEARTMATE 3™ LEFT VENTRICULAR ASSIST SYSTEM

Launched in the U.S.

Helps a weak heart pump blood in advanced heart failure patients awaiting further treatment, including heart transplants.

MR-CONDITIONAL LABELING FOR ELLIPSE™ ICD

Approved in the U.S.

One of Abbott’s most widely-used implantable cardioverter defibrillators is now approved to improve access for patients suffering from abnormally fast heart rhythms who may need an MRI scan in the future.

Leadership in DIAGNOSTICS

POINT OF CARE

Abbott is now the world leader in point of care testing.

GAME-CHANGING TECHNOLOGY†

Abbott continues to launch its new Alinity™ diagnostics systems designed to increase laboratory efficiency while providing quality results.

3Q 2017 PERFORMANCE

#1

†Not available for sale in the United States.